Vertex Pharmaceuticals (VRTX) Gets a Buy from J.P. Morgan
In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...
AZoM on MSN1d
Bruker Launches the VERTEX NEO Platform
Bruker Corporation today announced the launch of the VERTEX NEO Platform today with its first product, the VERTEX NEO R. This ...
FiercePharma8d
Vertex scores FDA nod for long-awaited non-opioid pain reliever Journavx
Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...
CNET on MSN4h
Google Gemini 2.0 AI Is Out Now. Here Are the Highlights
Google delivered big artificial intelligence news this week, launching the next generation of its chatbot, Gemini 2.0. Google ...
American Association of Individual Investors5d
Which Is a Better Investment, Vertex, Inc. or Workiva Inc. Stock?
Learn more about whether Vertex, Inc. or Workiva Inc. is a better investment based on AAII's A+ Investor grades, which ...
Gemini 2.0 is here for all, but all the different versions are getting confusing
The new Gemini 2.0 is now here for everyone to try. Google has announced that the latest version of their flagship AI model ...
US FDA approves Vertex's non-opioid painkiller
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
Vertex Pharmaceuticals: Strong Buy Rating Driven by Journavx Approval and Market Expansion Opportunities
Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...
Google releases Gemini 2.0 Flash for AI Studio and Vertex AI
Gemini 2.0 Flash is the base model that powers the free version of Gemini. It replaces Gemini 1.5 Flash which was released ...
American Association of Individual Investors4d
Which Is a Better Investment, Pegasystems Inc. or Vertex, Inc. Stock?
Learn more about whether Pegasystems Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
Vertex Pharmaceuticals' SWOT analysis: stock poised for growth amid pipeline expansion
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...